Interpace Diagnostics to Present New Data at the 88th Annual Meeting of the American Thyroid Association (ATA) on October 5th
01 oct. 2018 06h55 HE
|
Interpace Diagnostics Group, Inc.
ThyGenX® and ThyraMIR® Data from Clinical Experience Study to be Featured at ATA Product Expo PARSIPPANY, NJ, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Announces Reimbursement Expansion of ThyGeNEXT™
24 sept. 2018 06h55 HE
|
Interpace Diagnostics Group, Inc.
State of Pennsylvania and New York Approve Commercialization of New Thyroid Cancer Test PARSIPPANY, NJ, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG), announced...
Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups
17 sept. 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
Interpace Employees Participate in Local Events in Support of Lustgarten Foundation for Pancreatic Cancer Research, Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer Action Network ...
INTERPACE DIAGNOSTICS ANNOUNCES PARTICIPATION AT THE 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE SPONSORED BY H.C.WAINWRIGHT & CO.
27 août 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...
Interpace Diagnostics to Present at the 10th Annual Next Generation Dx Summit 2018
20 août 2018 16h30 HE
|
Interpace Diagnostics Group, Inc.
Discussing Methods for Securing Coverage and Reimbursement for Molecular Diagnostics PARSIPPANY, NJ, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Acquires Select Assets of Rosetta Genomics Out of Bankruptcy
15 août 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
Several Former Rosetta Employees and Select Customers Also Join Interpace Parsippany, NJ, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the...
Interpace Diagnostics Group Reports Second Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
09 août 2018 16h46 HE
|
Interpace Diagnostics Group, Inc.
Revenue Grew 43% Over the Prior Year’s Quarter and 14% Over the Prior Period Record Quarterly Revenue of $5.5 Million Cash & Cash Equivalents of $10.1 Million with No Long-Term Debt Now Covered...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Thursday, August 9, 2018
01 août 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc., (“Interpace” or “the Company”) announced today that it will report its second quarter 2018 financial results...
Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
31 juil. 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, July 31, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...